A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, Or Peduncular High-Grade Glioma

Trial Profile

A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, Or Peduncular High-Grade Glioma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Temozolomide
  • Indications Glioma
  • Focus Therapeutic Use
  • Acronyms HERBY
  • Sponsors Roche
  • Most Recent Events

    • 07 Feb 2018 Primary endpoint (Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC)) has not been met, according to results published in the Journal of Clinical Oncology.
    • 07 Feb 2018 Results (n=121) assessing bevacizumab (avastin) in combination with temozolomide (tmz) and radiotherapy in paediatric and adolescent participants with high-grade giloma, were published in the Journal of Clinical Oncology.
    • 19 Dec 2017 Planned End Date changed from 31 Mar 2020 to 10 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top